Transcode Therapeutics, Inc.
RNAZ· Nasdaq
RNAZTranscode Therapeutics, Inc.
Filed Aug 23, 2021 · 10-Q · 54 days after period end · 0001104659-21-108604
| Metric | Q2 2021 | Q2 2020 |
|---|---|---|
| Net Income | $2.77M | -$127.20K |
| EPS Diluted | $0.51 | -$0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Transcode Therapeutics, Inc. · CIK 1829635 · Engraved from SEC EDGAR
ended Jun 30, 2021 · filed Aug 23, 2021 · 54 d after period end
